Key Takeaways
- Core domestic business fires on all cylinders: Domestic volume grew 43% (like-to-like 26%), with talc, Navratna, and strategic investments all delivering standout performances.
- Gross margin hit is transitory, not structural: 520 bps of YoY compression split roughly 400 bps raw material and 120 bps mix; management expects input cost relief to flow through next year.
- International disruptions are clearing: Revenue declined only 2% despite Nepal floods and Iraq supply blockages; management declared the worst is behind us, with the last three months already in the green.
- Strategic investments are scaling fast but normalizing: The portfolio grew 73% like-to-like and now contributes ~26% of domestic business, though management flagged that 70% growth rates are not sustainable long-term.
- What to watch next quarter: Whether the AI platform goes live on schedule and starts delivering real gains from April, the trajectory of gross margin as higher-cost inventory flows through H2, and the pace of the baby care and Kesh King Scalp First launches.
Domestic Growth Engine
- Volume-led broad-based surge: Domestic sales grew 49% with volume up 43%, the strongest quarter in recent memory for the core portfolio. On a like-to-like basis, domestic business grew 32% with volume growth of 26%.
- Skincare dominance: The segment grew 31%, powered by the talc portfolio more than doubling, BoroPlus growing near 20%, and Fair and Handsome in double digits.
- Hair and scalp care momentum: Grew 30% with Navratna Oil in the 30s, Kesh King in high teens, and 7 Oils in One nearly doubling sales.
- Healthcare steady: The range grew 11%, with pain management in teens, OTC in high teens, and the Medico range in steady single-digit growth.
- Channel transformation underway: Organized channels now account for 37% of domestic business, and QuickCom alone represents ~15% of digital sales, reflecting a structural shift in how consumers reach Emami's products.
- Rural is a mixed bag: Markets in the south and west, where drought-like conditions prevailed, underperformed for some brands, while districts with good rainfall performed very well.
Mohan Goenka: "At this point of time, we are not really thinking of 0.5%, 1% here and there. Wherever we are finding opportunities, we are wanting to spend on advertising."
Strategic Investments Portfolio
- Scale and contribution: The portfolio grew 73% on a like-to-like basis and now contributes ~26% of domestic business. Axiom and Brillare more than doubled, IncNut grew over 50%, and The Man Company over 30%.
- The Man Company turnaround: After a period of stagnation, margins have moved to the high 20s and the brand grew 30%+ this quarter, driven by reformulation, improved product offerings, and marketing aligned to consumer expectations.
- Growth sustainability caveat: Management cautioned that sustaining 70% growth requires every brand to fire simultaneously; if even one slips, the aggregate number drops. The outlook is for strong growth levers across all four, but not at the current blistering pace.
- Distribution expansion: Axiom expanded in modern trade and QuickCom with visibility investments for AloFrut; IncNut moved beyond D2C into marketplaces, commenced QuickCom operations, and entered new international markets.
- Full-year scale: The portfolio is expected to deliver ₹800-850 crores this year, with plans for new talent, R&D, new products, and some brands entering general trade.
Dhruv Aggarwal: "To achieve this kind of growth, I think everything has to fire. Even if one of the brands goes down, you will not see these sort of numbers. So, longish, will we continue to see a 70%? Probably not, but definitely strong growth levers across all four."
International Business Reset
- Headline decline masks underlying recovery: Revenue declined 2%, but this was entirely driven by two specific external shocks: severe floods in Nepal and supply chain disruptions in Gulf markets from regional conflicts. Excluding Nepal and Iraq, international business grew 6%.
- Iraq supply routes restored: Iraq suffered almost zero sales in Q2 because goods could not be moved at all. Alternate routes have now been found through Port Aqaba, resolving the blockage.
- Bangladesh and GCC turned around: Business has turned around in both markets, with growth observed over the last two to three months. October was positive and in high double digits for international business overall.
- One unresolved constraint: OTC pain management goods categorized as hazardous due to spray and gaseous formats still face curtailed movement out of India, impacting roughly 2% of global business. This issue is specific to Emami's product mix and does not affect peers with different portfolios.
- Trajectory confirmed: The last three months (August, September, October) have all been in green territory, and management stated the worst is behind the international business.
Vivek Dhir: "I think worst is behind us in international."
Margins & Cost Structure
- Gross margin compression decomposed: The 520 bps YoY decline splits into approximately 400 bps from raw material cost inflation and 120 bps from business mix changes following the integration of acquired businesses.
- H2 inventory headwind: Second-half raw material costs will be higher because inventory was procured at elevated prices. The benefit of input cost corrections will flow through next year, not in the immediate quarters.
- Operating leverage delivered: Despite the gross margin pressure, EBITDA grew 25% to ₹222 crores and PBT grew 29% to ₹194 crores, reflecting the resilience of the business model and effective cost management.
- PAT decline is a tax story: PAT was lower by 3% at ₹144 crores, entirely due to the normalization of the effective tax rate as fiscal benefits phased out, not operational weakness.
- A&P discipline with flexibility: Full-year A&P is expected to stay in the 18-19% range, though management is willing to spend where opportunities arise rather than optimize for fractions of a percent.
Mohan Goenka: "I am very confident, Arnab, that once we see these, the second half is going to be higher because we have procured it at these prices now. Now, I think going forward, we should benefit out of these input corrections, which will be for next year."
Product & Innovation Pipeline
- Kesh King Scalp First range: Launched in modern trade and e-commerce, positioned as a premium extension of the brand with products priced ₹500-₹1,000. The range relies heavily on R&D differentiation, with unique ingredients marketed as detoxifying scalp serum, targeting consumers who read labels.
- BoroPlus baby care entry: Launched on e-commerce and modern trade, positioned as Ayurveda with ingredients like special almonds and Kashmiri kesar. Priced 25-50% cheaper than competing products, with management signaling increased focus on the baby care range this time.
- AI platform progressing ahead of schedule: The company is digitizing and applying AI to end-to-end processes from forecasting through fulfillment. Pilot phases in some markets are already showing impressive results, with full completion expected next quarter and real gains anticipated from April onwards.
Mohan Goenka: "We are heavily relying on the R&D side of it, because if you see into the details of it has some ingredients which are unique. We are calling it detoxifying scalp and scalp serum. So, we are relying heavily on the R&D. The consumers have become very intelligent. They now read the labels."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Core business growth | 18-20% growth for total core business | H2 FY27 |
| Strategic investments revenue | ₹800-850 crores | FY27 |
| A&P spend ceiling | 18-19% of revenue max | FY27 |
| AI platform completion | Platform live, real gains begin | Next quarter; April onwards |
| Gross margin recovery | Benefit from input cost corrections | Next year (FY28) |
| International trajectory | Already in green for last three months; worst behind | Now |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated revenue | ₹1,088 cr, +36% YoY |
| Domestic sales growth | +49% YoY, volume growth of 43% |
| Like-to-like consolidated sales growth | +24% YoY, adjusting for Axiom and IncNut Digital prior period |
| Like-to-like domestic business growth | +32% YoY, volume growth of 26% |
| EBITDA | ₹222 cr, +25% YoY |
| Profit before tax | ₹194 cr, +29% YoY |
| Profit after tax | ₹144 cr, -3% YoY, due to tax rate normalization |
| Gross margin change | -520 bps YoY, of which 400 bps from RM cost and balance from mix |
| A&P spends ratio | ~20% last year, expected 18%-19% for full year |
| Price increase taken | 5.5% for the full year |
| Strategic investments portfolio growth | +73% like-to-like YoY, contributed ~26% of domestic business |
| Strategic investments full-year guidance | ₹800 cr+ |
| International business revenue | -2% YoY, -7% YoY per analyst; +6% excluding Nepal and Iraq (Note: the -7% figure was stated by an analyst, not confirmed by management) |
| Organized channels share of domestic business | 37% |
| QuickCom share of digital sales | ~15% |
| Share buyback completed | ₹281 cr, 73 lakh shares bought back |
| First interim dividend | ₹5 per share, payout of ₹214 cr |